Latest Period
Q4 2025
Security Snapshot
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) Institutional Ownership
CUSIP: 00166B105
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
55
Shares (Excl. Options)
29,193,302
Price
$1.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ALXO on Nasdaq
- Shares outstanding
- 132,570,600
- Price per share
- $2.00
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 29,193,302
- Total reported value
- $33,447,411
- % of total 13F portfolios
- 0%
- Share change
- +1,323,706
- Value change
- +$624,566
- Number of holders
- 55
- Price from insider filings
- $2.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share is tracked under CUSIP 00166B105.
- 55 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 55 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $33,447,411 to $122,822.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 55 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00166B105:
Significant Owners of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| venBio Global Strategic Fund, L.P. | 10% | $14,547,038 | 13,163,549 | GOODMAN COREY S | 02 Feb 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $16,265,211 | 13,117,106 | RA Capital Management, L.P. | 02 Feb 2026 | |||
| TCG Crossover GP II, LLC | 9.9% | $14,703,389 | 13,011,849 | Chen Yu | 30 Jan 2026 | |||
| Redmile Group, LLC | 8.5% | $2,042,240 | 4,641,455 | Redmile Group, LLC | 30 Jun 2025 | |||
| HBM Healthcare Investments (Cayman) Ltd. | 8.4% | +27% | $2,295,000 | +$547,266 | 4,500,000 | +31% | HBM Healthcare Investments (Cayman) Ltd. | 31 Mar 2025 |
| TANG CAPITAL PARTNERS LP | 6.3% | $1,681,410 | 3,296,883 | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| MILLENNIUM MANAGEMENT LLC | 1.5% | -75% | $3,947,290 | -$2,381,279 | 1,988,559 | -38% | Millennium Management LLC | 31 Mar 2026 |
| FMR LLC | 3.4% | $917,426 | 1,798,875 | FMR LLC | 29 Nov 2024 |
As of 31 Dec 2025, 55 institutional investors reported holding 29,193,302 shares of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO). This represents 22% of the company’s total 132,570,600 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| venBio Partners LLC | 7.3% | 9,699,925 | 0% | 5.1% | $10,960,915 |
| Redmile Group, LLC | 2.5% | 3,264,718 | -2% | 0.27% | $3,689,131 |
| MILLENNIUM MANAGEMENT LLC | 2.4% | 3,204,619 | +22% | 0% | $3,621,219 |
| Almitas Capital LLC | 1.9% | 2,536,891 | 0% | 0.63% | $2,866,687 |
| VANGUARD GROUP INC | 1.2% | 1,630,940 | +6.7% | 0% | $1,842,962 |
| Driehaus Capital Management LLC | 1.1% | 1,422,882 | +79% | 0.01% | $1,607,857 |
| ACADIAN ASSET MANAGEMENT LLC | 1% | 1,374,273 | +13% | 0% | $1,552,000 |
| UBS Group AG | 0.65% | 865,991 | +402% | 0% | $978,570 |
| TWO SIGMA ADVISERS, LP | 0.54% | 710,400 | -1.3% | 0% | $802,752 |
| TWO SIGMA INVESTMENTS, LP | 0.48% | 640,205 | +5.5% | 0% | $723,432 |
| BANK OF AMERICA CORP /DE/ | 0.4% | 531,845 | +0.19% | 0% | $600,985 |
| BANK OF MONTREAL /CAN/ | 0.36% | 474,781 | 0% | 0% | $536,503 |
| BlackRock, Inc. | 0.34% | 450,430 | +0.61% | 0% | $508,986 |
| RENAISSANCE TECHNOLOGIES LLC | 0.32% | 423,099 | +157% | 0% | $478,102 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.27% | 353,696 | +0.39% | 0% | $399,827 |
| JANE STREET GROUP, LLC | 0.14% | 185,961 | +3.1% | 0% | $210,135 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.11% | 151,027 | +34% | 0% | $170,661 |
| NORTHERN TRUST CORP | 0.11% | 149,097 | +57% | 0% | $168,480 |
| STATE STREET CORP | 0.09% | 124,228 | +11% | 0% | $140,378 |
| Seven Fleet Capital Management LP | 0.09% | 117,817 | 0% | 0.09% | $133,133 |
| BANK OF NOVA SCOTIA | 0.08% | 105,858 | 0% | 0% | $119,620 |
| GSA CAPITAL PARTNERS LLP | 0.07% | 92,654 | +5.1% | 0.01% | $105,000 |
| IEQ CAPITAL, LLC | 0.07% | 92,233 | 0% | 0% | $104,223 |
| MORGAN STANLEY | 0.06% | 83,757 | -1.8% | 0% | $94,646 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.06% | 76,072 | +111% | 0% | $85,961 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 61,820 | $122,822 | -$19,700 | $2.00 | 5 |
| 2025 Q4 | 29,193,302 | $33,447,411 | +$624,566 | $1.13 | 55 |
| 2025 Q3 | 27,785,299 | $51,273,440 | +$2,395,861 | $1.83 | 60 |
| 2025 Q2 | 29,030,607 | $12,060,366 | -$2,784,536 | $0.42 | 58 |
| 2025 Q1 | 34,764,459 | $21,657,278 | -$4,297,920 | $0.62 | 83 |
| 2024 Q4 | 41,028,903 | $68,515,761 | -$8,509,648 | $1.67 | 85 |
| 2024 Q3 | 45,458,855 | $83,126,108 | -$40,248,836 | $1.82 | 90 |
| 2024 Q2 | 48,509,608 | $292,389,850 | -$2,826,841 | $6.03 | 107 |
| 2024 Q1 | 45,776,694 | $510,423,087 | -$5,822,832 | $11.15 | 105 |
| 2023 Q4 | 45,764,823 | $681,456,826 | +$185,269,081 | $14.89 | 93 |
| 2023 Q3 | 33,283,050 | $159,762,120 | -$6,348,070 | $4.80 | 75 |
| 2023 Q2 | 34,283,564 | $257,462,824 | -$6,376,897 | $7.51 | 74 |
| 2023 Q1 | 35,697,467 | $161,353,578 | -$6,004,481 | $4.52 | 85 |
| 2022 Q4 | 36,433,730 | $410,607,954 | -$2,049,707 | $11.27 | 85 |
| 2022 Q3 | 36,439,308 | $348,724,761 | +$5,422,376 | $9.57 | 96 |
| 2022 Q2 | 35,930,829 | $290,675,201 | -$16,579,357 | $8.09 | 92 |
| 2022 Q1 | 36,794,716 | $621,886,079 | +$2,845,527 | $16.90 | 94 |
| 2021 Q4 | 36,290,670 | $779,906,251 | -$55,903,331 | $21.49 | 103 |
| 2021 Q3 | 34,508,619 | $2,548,791,083 | +$109,794,972 | $73.86 | 113 |
| 2021 Q2 | 33,314,685 | $1,821,610,718 | -$28,517,807 | $54.68 | 102 |
| 2021 Q1 | 33,493,682 | $2,466,083,905 | +$80,496,245 | $73.74 | 90 |
| 2020 Q4 | 32,294,048 | $2,779,048,270 | +$439,356,967 | $86.20 | 89 |
| 2020 Q3 | 27,250,196 | $1,027,708,220 | +$1,027,708,220 | $37.74 | 56 |